Consequently, the combination of MyD88 inhibitor and PD-1 mAbs resulted in a significant reduction in murine melanoma size and infiltration of F4/80+ CD11b+ macrophages, thereby increasing the recruitment of CD8+ T cells. Here, PDCD1 is linked to melanoma.